PRQR proqr.com: Market Capitalization to Book Value Ratio

Official company branding of ProQR Therapeutics NV (PRQR)

The ProQR Therapeutics N.V. (PRQR) licensing platform generates a steady cash flow, as confirmed by the price action chart at the 2.07 level. The business relies on advanced RNA editing methods to combat genetic pathologies, including the treatment of vision loss. Process efficiency is supported by precise cold-chain drug transportation, which guarantees component integrity and high distribution margins.

proqr.com (PRQR): Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for ProQR Therapeutics N.V. (PRQR)

- price and consensus price forecast:
Price Chart proqr.com|PRQR - Fair Value Consensus
- market capitalization data:
Market Capitalization ProQR Therapeutics NV|PRQR - Business Value
- book capitalization data:
Net Assets per Single Share ProQR Therapeutics N.V.|PRQR - Accounting Capitalization|Market Capitalization to Book Value Ratio proqr.com|PRQR - Company Total Assets
- debt and liquidity data:
Debt to Equity ProQR Therapeutics N.V.|PRQR - Long-Term Liabilities to Equity|Short-Term Debt to Equity proqr.com|PRQR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ProQR Therapeutics NV
Fundamental valuation:ProQR
Signature product of proqr.com

To build a high-quality portfolio, it is essential to track the price-to-book ratio, which measures the premium for future growth relative to current capital. For ProQR Therapeutics N.V. (PRQR), whose model is based on the full outsourcing of production and R&D, the extent to which market capitalization exceeds book value reflects the value of intellectual property and patents rather than tangible assets.

Direct competitors

Market Value to Book Value Ratio Tempus Labs TEM|qiagen.com (QGEN) - Market Value to Book Value|Market Capitalization to Book Value Ratio Ionis (IONS)|Capitalization to Book Value Ratio RGEN|Market Value to Book Value Ratio Avidity RNA|Capitalization to Book Value Ratio CRISPR (CRSP)|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|ultragenyx.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Beam Therapeutics|SRPT: Market Capitalization to Net Assets|Market Value to Book Value Ratio Twist Bio TWST|TXG (10x) - Market Value to Book Value|Market Value to Book Value Ratio NTLA (Intellia Therapeutics)|Market-to-Book Ratio STOK|BLFS: Market Value to Book Value Ratio|Market Value to Equity Ratio WVE (Wave Life Sciences Ltd)|Market Value to Book Value Ratio Maze Tx|SION - Market Value to Book Value|Market Cap to Net Assets Ratio Prime Medicine, Inc. (PRME)|tayshagtx.com (TSHA) - Market Value to Book Value|QURE - Market Cap to Net Assets Ratio|MeiraGTx Holdings (MGTX) - Market Cap to Book Value Multiple|RGNX - Market Capitalization to Book Value Ratio|Market Value to Book Value Solid Corp|Ocugen, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio PACB (pacb.com)|Market Value to Book Value Ratio Benitec Biopharma|Market Value to Book Value Design Therapeutics Inc DSGN|Rocket Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|FDMT: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio lexeotx.com (LXEO)|Korro Bio (KRRO) - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio EDIT (Editas Medicine)|Market-to-Book Ratio Silence Therapeutics PLC (SLN)|Market Cap to Net Assets Ratio CDXS|Market Capitalization to Book Value Ratio Sangamo BioSciences SGMO|Market Cap to Net Assets Ratio Nautilus Bio (NAUT)|Market Cap to Book Value Multiple metagenomi.co MGX|Market Capitalization to Book Value Ratio DTIL (Precision BioSciences)|GBIO - Market Capitalization to Book Value|BOLD (Boundless Bio, Inc) - Market Capitalization to Book Value Ratio|XCUR (Exicure) - Market Cap to Net Assets Ratio|IMNN: Market Value to Book Value Ratio|Market Capitalization to Book Value RXi Pharmaceuticals (PHIO)|Mustang Bio, Inc. (MBIO) - Market Cap to Net Assets Ratio|Market Value to Book Value RNAZ (transcodetherapeutics.com)|BNGO - Market Value to Book Value Ratio|APDN - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio BLUE (bluebird bio, Inc.)|ImmunoPrecise Antibodies (IPA) - Market Capitalization to Book Value|Omega Therapeutics, Inc. (OMGA) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Singular Genomics Systems, Inc.|RGLS: Market Cap to Net Assets Ratio|Market Capitalization to Book Value SYRS|TBIO - Market Value to Book Value Ratio|Market Capitalization to Net Assets TCON (traconpharma.com)|Market Value to Book Value Ratio Unity Biotechnology, Inc.